Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial

Recruiting Phase 3 Interventional Study
Pulmonary Tuberculosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
20 – 99
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
270 (estimated)
Sponsor
Kaohsiung Veterans General Hospital. · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Tuberculosis remains an important global health problem, and the world is currently not on track to end the TB epidemic by 2030. With the concerted efforts of the government and medical community, the incidence of TB in Taiwan has gradually decreased, however, Taiwan remains an endemic area for TB. The development of efficacious, safe, and shorter treatment regimens could significantly improve tre…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Newly diagnosed pulmonary tuberculosis patients combined with any of the following diagnostic conditions: * at least one set of sputum specimens is positive for Mycobacterium tuberculosis culture or TB PCR test; or * pathological and histological findings of typical tuber…
Contacts

Susan Shin-Jung Lee, M.D., Ph.D.

+886-7342-2121

ssjlee28@yahoo.com.tw

CONTACT

Mei-Ling Lin, University

+886-7342-2121

ed101622@gmail.com

CONTACT